Abstracts tagged "Intervention"

Abstract Number: 0317 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Martijn Gerritsen², Jos W.R. Twisk¹, Martin van der Esch², Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced The Western…
Abstract Number: 2597 • ACR Convergence 2023
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis and Lower Gastrointestinal Tract Symptoms: Data from the ReSScue Phase 2 Randomized Clinical Trial
Anna-Maria Hoffmann-Vold¹, Havard Fretheim¹, Imon Barua¹, Maylen Nordgård Carstens¹, Henriette Didriksen², Vikas Sarna¹, Knut AE Lundin¹, Oliver Distler³, Dinesh Khanna⁴, Elizabeth Volkmann⁵, Oyvind Midtvedt¹, Tore Midtvedt⁶, Alvilde Dhainaut⁷, Anne-Kristine H Halse⁸, Gunnstein Bakland⁹, Inge Olsen¹, Maiju E Pesonen¹ and Oyvind Molberg¹⁰, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Moss, Norway, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Michigan, Ann Arbor, MI, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷St. Olav, Trondheim, Norway, ⁸University Hospital Bergen, Bergen, Norway, ⁹University Hospital of North Norway, Tromsø, Norway, ¹⁰Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Lower gastrointestinal tract (GIT) complications are common in patients with systemic sclerosis (SSc), associate with a high disease burden, and current treatment alternatives are…
Abstract Number: 0328 • ACR Convergence 2023
From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Marc Blanchard¹, Pedro Ming Azevedo², Tiffany Prétat², Cinja Koller² and Thomas Hügle³, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²Lausanne University Hospital, Lausanne, Switzerland, ³Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately…
Abstract Number: PP01 • ACR Convergence 2023
You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…
Abstract Number: 0470 • ACR Convergence 2023
Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic
Caroline Siegel¹, Deanna Jannat-Khah¹, Avi Mikhaylov¹, Erika Abramson², Nancy Pan¹ and Lisa Sammaritano³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Only one-third of reproductive-aged women with rheumatic disease (RD) are prescribed effective contraception, even if prescribed teratogenic medications (Talabi et al. Arthritis Care Res.…
Abstract Number: 1009 • ACR Convergence 2023
More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid
larry hearld, Jasvinder Singh and Mark Beasley, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess the association of the number of implementation strategies for a patient lupus decision aid (DA) with perceived implementation outcomes, and the moderating…
Abstract Number: 1012 • ACR Convergence 2023
Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Candace Feldman¹, Katherine Crum², Kaitlin Hanken³, Constance Fontanet⁴, Ellen Sears², Theresa Oduol², Seanna Vine², Juliana Mastrorilli², Gauri Bhatkhande², Julie Lauffenburger², Rebecca Oran⁵, Ted Robertson⁶, Wendy Wood⁷ and Niteesh Choudhry³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Center for Healthcare Delivery Sciences and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Darmouth Geisel School of Medicine, Hanover, NH, ⁵BCBS, Boston, MA, ⁶Ideas42, San Francisco, CA, ⁷USC, Los Angelos, CA
Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…
Abstract Number: 1090 • ACR Convergence 2023
Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center
Shelby Gomez¹, Trisha Ludwig¹, Katherine Hartkopf², Sancia Ferguson³, Lori Zemlicka⁴, Mindy Jones⁵ and Christie M. Bartels⁶, ¹UW Health Pharmacy, Madison, WI, ²Pharmacy Society of Wisconsin, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴UW Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: We embedded a clinical pharmacist into our university rheumatology clinics beginning in June 2022 to improve patient experience and reduce provider burden based on…
Abstract Number: 0063 • ACR Convergence 2022
Implementability of a SLE Medication Adherence Intervention
Kai Sun¹, Nneka Molokwu², Amy Corneli¹, Kathryn Pollak¹, Alexandria Bennion², Jennifer L Rogers³, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Amanda Eudy⁴, Hayden Bosworth¹ and Megan Clowse², ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University School of Medicine, Division of Rheumatology & Immunology, Durham, NC, ⁴Duke University, Raleigh, NC
Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with…
Abstract Number: 0126 • ACR Convergence 2022
Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?
Rosemina Patel¹, Angie Ariza-hutchinson¹, Ahsan Iqbal¹, Matthew McElwee¹, N. Suzanne Emil¹, Sharon Nunez¹, maheshwari muruganandam¹, frank O'Sullivan¹, Roderick Fields¹, Yvonne Waters² and Wilmer Sibbitt¹, ¹University of New Mexico, Albuquerque, NM, ²University of New Mexico Hospital, Corrales, NM
Background/Purpose: Arthrocentesis of the painful but non-effusive knee is usually not undertaken due to a high arthrocentesis failure rate. We hypothesized that compression-assisted arthrocentesis of…
Abstract Number: 0173 • ACR Convergence 2022
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis
Victoria Werth¹, Barbara White², Josef Concha³, Josh Dan¹, Nancy Dgetluck², Kathleen Hally², Scott Constantine², Rohit Aggarwal⁴, David Fiorentino⁵, Ingrid Lundberg⁶ and Chester Oddis⁷, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Corbus Pharmaceuticals, Norwood, MA, ³Universiity of Pennsylvania/Dermatology, Philadelphia, PA, ⁴University of Pittsburgh, Division of Rheumatology, Pittsburgh, PA, ⁵Stanford university/Department of Dermatology, Palo Alto, CA, ⁶Karolinska Institute, Stockholm, Sweden, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Safe and effective treatments are of significant unmet need in DM. Lenabasum, a CB2 agonist that activates resolution of inflammation, improved skin disease, patient-reported…
Abstract Number: 0201 • ACR Convergence 2022
Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
Maurice Flurie¹, Joseph Coe², Monica Converse¹, Kristina Davidson³, Colton Flowers¹, Kelly Gavigan⁴, Daniel Hernandez⁵, Helen Hernandez¹, Gary Ho⁶, Brian LaMoreaux³, Christopher Parker⁶, E. Robert Wassman¹, Christopher DeFelice¹ and Maria Picone¹, ¹TREND Community, Philadelphia, ²Global Healthy Living Foundation, Upper Nyack, ³Horizon Therapeutics, Chicago, IL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Gout Support Group of America, Austin, TX
Background/Purpose: The ability to actively listen to and interpret the patient experience is vital to effectively address the needs of individuals within a particular community.…
Abstract Number: 0571 • ACR Convergence 2022
National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Anna Montgomery¹, Gary Tarasovsky², Mary Whooley², Jennifer Barton³, Karla Miller⁴, Holly Mitchell⁵, Jo Dana², Kimberly Reiter⁶, Elizabeth Wahl⁷, Karine Rozenberg-Ben-Dror⁸, Jing Li⁹ and Gabriela Schmajuk¹⁰, ¹University of California San Francisco, Reno, NV, ²San Francisco VA Medical Center, San Francisco, CA, ³VA Portland Health Care System/OHSU, Portland, OR, ⁴University of Utah Division of Rheumatology/VA Salt Lake City Health Care, Salt Lake City, UT, ⁵Ralph H. Johnson VA Hospital, Mount Pleasant, SC, ⁶Albuquerque VA Medical Center, Albuquerque, NM, ⁷VA Puget Sound Healthcare System, Seattle, WA, ⁸Greater Lakes Region/VISN 12 Dept Veterans Affairs, Hines, IL, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰UCSF / SFVA, San Francisco, CA
Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…
Abstract Number: 1269 • ACR Convergence 2022
Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
Sancia Ferguson¹, Lori Zemlicka², Amanda Weber², Abdul Halabi³, Jon Arnason⁴ and Christie Bartels⁵, ¹University of Wisconsin School of Medicine & Public Health, Madison, WI, ²UW Health, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin Hospitals and Clinics, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: The treat-to-target approach endorsed by the ACR for rheumatoid arthritis requires frequent monitoring of disease activity using validated instruments, with changes to the treatment…
Abstract Number: 1809 • ACR Convergence 2022
Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
Keigo Hayashi¹, yuqing zhang², Hyon Choi³ and Kazuki Yoshida⁴, ¹Brigham and Women's Hospital, Okayama, Japan, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Low-dose colchicine has been demonstrated to reduce cardiovascular (CV) events in two recent large cardiovascular trials. Gout patients, for whom colchicine is a highly relevant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].